CIK 0000939767 · Large accelerated filer
EXELIXIS, INC.
Sign in to watch- Ticker
- EXEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jan 1
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043257395
- Phone
- 6508377000
- Business address
- 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
- Former names
- EXELIXIS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-27 | Hessekiel Jeffrey EVP & General Counsel | Option exercise | +129,314 | $18.80 | $2.4M | 644,967 |
| 2024-11-27 | Hessekiel Jeffrey EVP & General Counsel | Shares withheld for taxes | −98,908 | $35.93 | $3.6M | 546,059 |
| 2024-11-27 | Hessekiel Jeffrey EVP & General Counsel | Option exercise · Option (right to buy) | −129,314 | 0 | ||
| 2024-11-22 | Haley Patrick J. EVP, Commercial | Sale 10b5-1 | −10,000 | $35.27 | $353K | 278,665 |
| 2024-11-18 | Haley Patrick J. EVP, Commercial | Sale 10b5-1 | −22,207 | $34.31 | $762K | 308,046 |
| 2024-11-18 | Haley Patrick J. EVP, Commercial | Sale 10b5-1 | −19,381 | $34.41 | $667K | 288,665 |
| 2024-11-15 | Senner Christopher J. EVP and CFO | Shares withheld for taxes | −17,506 | $35.05 | $614K | 704,174 |
| 2024-11-15 | MORRISSEY MICHAEL President and CEO | Shares withheld for taxes | −47,642 | $35.05 | $1.7M | 916,742 |
| 2024-11-15 | Haley Patrick J. EVP, Commercial | Shares withheld for taxes 10b5-1 | −14,672 | $35.05 | $514K | 330,253 |
| 2024-11-15 | Hessekiel Jeffrey EVP & General Counsel | Shares withheld for taxes | −14,672 | $35.05 | $514K | 515,653 |
| 2024-11-15 | Aftab Dana CSO/EVP Disc & Trans Research | Shares withheld for taxes | −12,838 | $35.05 | $450K | 486,107 |
| 2024-11-15 | Peterson Amy C. EVP Prod Dev & Med Aff & CMO | Shares withheld for taxes | −27,224 | $35.05 | $954K | 294,897 |
| 2024-11-05 | Aftab Dana CSO/EVP Disc & Trans Research | Option exercise 10b5-1 | +96,986 | $18.80 | $1.8M | 595,931 |
| 2024-11-05 | Aftab Dana CSO/EVP Disc & Trans Research | Sale 10b5-1 | −96,986 | $35.00 | $3.4M | 498,945 |
| 2024-11-05 | Aftab Dana CSO/EVP Disc & Trans Research | Option exercise · Option (right to buy) 10b5-1 | −96,986 | 0 | ||
| 2024-11-01 | Hessekiel Jeffrey EVP & General Counsel | Sale 10b5-1 | −50,000 | $34.13 | $1.7M | 530,325 |
| 2024-11-01 | POSTE GEORGE Director | Sale | −30,000 | $34.00 | $1.0M | 169,020 |
| 2024-10-31 | MORRISSEY MICHAEL President and CEO | Gift | −46,000 | 1,407,212 | ||
| 2024-10-30 | Aftab Dana CSO/EVP Disc & Trans Research | Sale 10b5-1 | −1,162 | $31.40 | $36K | 498,945 |
| 2024-10-28 | Hessekiel Jeffrey EVP & General Counsel | Sale 10b5-1 | −25,000 | $28.39 | $710K | 580,325 |
Page 12 of 20 · 381 trades